Antimicrobial activity of tigecycline against recent isolates of respiratory pathogens from Asian countries

Diagnostic Microbiology and Infectious Disease
Kwan Soo KoNam Yong Lee

Abstract

In vitro activities of tigecycline were compared with 15 other comparator agents against recent clinical isolates of respiratory pathogens (623 Streptococcus pneumoniae, 105 Staphylococcus aureus, 92 Klebsiella pneumoniae, and 84 Haemophilus influenzae isolates) collected from 11 Asian countries. All isolates of S. pneumoniae from Asian countries were susceptible to tigecycline regardless of penicillin susceptibility with MIC90 of <or=0.06 mg/L. Both methicillin-resistant and methicillin-susceptible S. aureus isolates were susceptible to tigecycline with very low MIC90 values (0.25 and 0.12 mg/L, respectively). Tigecycline was also active against K. pneumoniae (98.9% susceptible; MIC50, 1 mg/L; MIC90, 2 mg/L) including 10 extended-spectrum beta-lactamase-producing isolates and H. influenzae (100% susceptible; MIC50 and MIC90, 0.12 mg/L) from Korea. Data confirmed that tigecycline has an excellent in vitro activity against drug-resistant clinical isolates of respiratory pathogens from Asian countries.

References

Apr 15, 2000·Diagnostic Microbiology and Infectious Disease·K OhkusuK Sawada
Sep 19, 2000·Antimicrobial Agents and Chemotherapy·E J GoldsteinK Tyrrell
Apr 24, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·N Y LeeP C Appelbaum
Feb 19, 2002·Antimicrobial Agents and Chemotherapy·Carmen BetriuUNKNOWN Spanish Group of Tigecycline
Nov 25, 2004·Antimicrobial Agents and Chemotherapy·Jae-Hoon SongUNKNOWN Asian Network for Surveillance of Resistant Pathogens Study Group
Dec 8, 2004·Diagnostic Microbiology and Infectious Disease·Ying-yuan ZhangFu Wang
Aug 5, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Gary A Noskin
Aug 18, 2005·Diagnostic Microbiology and Infectious Disease·Helio S SaderThomas R Fritsche
Aug 18, 2005·Diagnostic Microbiology and Infectious Disease·Daryl J HobanUNKNOWN Tigecycline Evaluation and Surveillance Trial (TEST Program) Group

❮ Previous
Next ❯

Citations

Sep 11, 2009·BMC Pulmonary Medicine·Cristina TanaseanuUNKNOWN 313 Study Group
Jun 23, 2011·Infection and Drug Resistance·Mary L TownsendRichard H Drew
Jun 28, 2011·Nanomedicine : Nanotechnology, Biology, and Medicine·Maribel GuzmanStéphane Godet

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.